| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Gray Cameron serves as a Director at CUE. Across recent SEC filings that breaks down to 2 buys and 0 sells. Those positions are worth an estimated $20.0M at current prices.
The biggest single holding is CUE (~$20.0M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 10,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2020 | CUE Cue Biopharma, Inc. | Director | Buy | 10,000 | $15.15 | $151,500.00 | +0.7% |